Uncategorized – Page 10

Pharma stocks swerve as Trump hits pause on most tariffs

3 weeks ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

3 weeks ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats

3 weeks ago talkbio0Tagged chain disruption, drug manufacturing, Generalized, pharma policy, pharmaceutical tariffs, pharmaceutical trade war, Trump import tariffs, United States

Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

3 weeks ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.

Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy

3 weeks ago talkbio0Tagged Annexon, ANX005, Approved, GBS, Guillain-Barré syndrome, Move GBS Forward™, Phase 3, Phase 3 trial, Tanruprubart, Targeted Therapy, United States Food and Drug Administration

Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval

Drug pricing watchdog ICER offers ways to increase obesity drug access

3 weeks ago talkbio0Tagged Access, drug price, ICER, Obesity, Policy, Wegovy

ICER, Obesity, Access, Wegovy, Policy, drug price

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

3 weeks ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks

Former CBER head Peter Marks says he blocked RFK Jr. from vaccine safety database before leaving FDA: AP

3 weeks ago talkbio0Tagged Disease Outbreaks, Kennedy, Kennedy 's, Massive, Peter Marks, RFK Jr., United States Food and Drug Administration, Vaccine Safety, Vaccines, VAERS

Vaccines, Massive, Vaccine Safety, Kennedy, United States Food and Drug Administration, RFK Jr., Disease Outbreaks, Peter Marks, VAERS, Kennedy ‘s

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

3 weeks ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial

3 weeks ago talkbio0Tagged Autoimmune Diseases, Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, CAR-T, Cartesian, Clinical Trials, gMG, mRNA-based, Myasthenia Gravis, Phase III AURORA trial

Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results